TalkMed Group Limited

Equities

5G3

SG2G61000003

Healthcare Facilities & Services

Market Closed - Singapore S.E. Other stock markets 01:25:41 2024-06-03 am EDT			5-day change	1st Jan Change
0.395 ^SGD	0.00%		0.00%	+3.95%

May. 23	TalkMed’s Subsidiary Enters Sale and Purchase Agreement to Dispose Shares in Unit	MT
May. 17	TalkMed in Preliminary Acquisition Talks	MT

Talkmed Group Limited Announces Change of Joint Company Secretary

September 01, 2021 at 06:15 am EDT

TalkMed Group Limited announced that Ms. Jacqueline Anne Low has been appointed as Secretary of the Company, in place of Ms. Dai Lingna who has resigned as Secretary of the Company, with effect from 1 September 2021. Following the aforesaid, Ms. Jacqueline Anne Low shall act as Company Secretary jointly with Mr. Lee Boon Yong and Mr. Lim Heng Chong Benny, the current Joint Secretaries of the Company. The Board wishes to thank Ms. Dai Lingna for her past services rendered to the Company.

Latest news about TalkMed Group Limited

TalkMed’s Subsidiary Enters Sale and Purchase Agreement to Dispose Shares in Unit	May. 23	MT
TalkMed in Preliminary Acquisition Talks	May. 17	MT
TalkMed Group Limited Approves Final One-Tier Tax-Exempt Dividend for the Financial Year Ended 31 December 2023	Apr. 18	CI
TalkMed Reaches Final Settlement in Mediation Related to Claims in Stem Med Stake Disposal	Apr. 16	MT
TalkMed Group Awards 1.1 Million New Shares	Mar. 13	MT
TalkMed's H2 Attributable Profit Falls on Wider Impairment Loss	Feb. 20	MT
Talkmed Group Limited Proposes Tax Exempt (One-Tier) Final Dividend for the Financial Year Ended 31 December 2023, Payable on 10 May 2024	Feb. 20	CI
TalkMed Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
TalkMed Group Grants Nearly 8 Million Share Awards Under Performance Share Plan	Dec. 20	MT
TalkMed Group Limited Announces Management Changes	Nov. 10	CI
TalkMed Group Limited Announces Re-Designation of Leong Ching Ching from Non-Executive Director to Independent Non-Executive Director and Appoints as Chairman of the Remuneration Committee, Effective January 1, 2024	Nov. 10	CI
TalkMed Group Limited Announces Re-Designation of S. Chandra Das from Independent Non-Executive Director to Non-Independent Non-Executive Director, Effective 1 January 2024	Nov. 10	CI
TalkMed Group Limited Announces Re-Designation of Sitoh Yih Pin from Independent Non-Executive Director to Non-Independent Non-Executive Director, Effective 1 January 2024	Nov. 10	CI
Talkmed Group Limited Appoints Khoo Kei Siong as Alternate Director to Ang Peng Tiam, Effective January 1, 2024	Nov. 10	CI
TalkMed Group Limited Appoints Dr Tan Khai Tong as Independent Non-Executive Director, Member of the Remuneration Committee, Effective January 1, 2024	Nov. 10	CI
TalkMed Group Limited Appoints Peter Sim Swee Yam as Independent Non-Executive Director, Chairman of the Nominating Committee, Member of the Audit and Risk Committee, Effective January 1, 2024	Nov. 10	CI
TalkMed Group Limited Appoints Lam Kok Shang as Independent Non-Executive Director, Chairman of the Audit and Risk Committee, Member of the Nominating Committee, Effective January 1, 2024	Nov. 10	CI
TalkMed Group Issues New Shares Upon Vesting of Share Awards	23-10-19	MT
TalkMed Group Issues New Shares Upon Vesting of Share Awards	23-10-17	MT
Singapore Stocks Track Global Gains to Close Higher; Delfi Shares Jump 3% on Higher H1 Profit, Revenue	23-08-08	MT
TalkMed Group's Attributable Profit Zooms 18% in H1	23-08-08	MT
TalkMed Group Limited Declares Tax Exempt (One-Tier) Interim Dividend for the Financial Year Ending 31 December 2023, Payable on 22 August 2023	23-08-07	CI
TalkMed Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-07	CI
TalkMed Group Establishes New Subsidiary for Cell, Gene Therapy	23-07-07	MT
TalkMed Group Limited Approves the Final One-Tier Tax-Exempt Dividend in Respect of 2022	23-05-16	CI

Chart TalkMed Group Limited

Duration

Period

More charts

Company Profile

TalkMed Group Limited is a Singapore-based investment holding company. The Company provides medical oncology and palliative care healthcare services. Its segments include Oncology services, and Cellular and gene therapy related products and services. Oncology services segment comprises medical oncology services targeting various cancers, such as breast cancer, colon cancer, lung cancer, liver, biliary and pancreatic cancers, gastro-intestinal cancers, head and neck cancers, leukemia, hematology malignancies and brain cancer. It includes Parkway Cancer Centre, Thu Cuc International General Hospital. The Cellular and gene therapy related products and services segment includes provision of goods and services related to cellular and gene therapy through its subsidiaries, CellVec Pte. Ltd., and BioCell Innovations Pte. Ltd. The Company, through the Parkway Cancer Centre (PCC)-vehicle, offers a support system to cater to the psychosocial needs of its patients and their families.

Sector

Healthcare Facilities & Services

Calendar

2024-07-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
TALKMED GROUP LIMITED	+3.95%	388M
HCA HEALTHCARE, INC.	+23.08%	88.99B
CVS HEALTH CORPORATION	-23.80%	74.82B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+1.06%	26.63B
FRESENIUS SE & CO. KGAA	+3.88%	17.88B
LABCORP HOLDINGS INC.	-13.76%	16.43B
QUEST DIAGNOSTICS INCORPORATED	+2.87%	15.77B
TENET HEALTHCARE CORPORATION	+79.44%	13.21B
NATERA, INC.	+70.00%	13.08B
DAVITA INC.	+38.76%	12.9B

Other Healthcare Facilities & Services